Showing results (11-20 of 54) with videos related to
Sort By:
Pageof 6
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancerPetr Zatloukal, Radj Gervais, Johan Vansteenkiste, et al.Case Reports in Oncology|April 16, 2015
EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case ReportEric Dansin, Aurélien Carnot, Véronique Servent, et al.The Lancet. Oncology|July 24, 2010
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyLucio Crinò, Eric Dansin, Pilar Garrido, et al.Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble formMarie-Christine Copin, Marie Lesaffre, Mélanie Berbon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumorsIsa E L M Kuppens, Eric Dansin, Henk Boot, et al.BMC Cancer|August 2, 2018
Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trialDiane Pannier, Antoine Adenis, Emilie Bogart, et al.Clinical Lung Cancer|June 1, 2019
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine PracticePhilippe Jamme, Clotilde Descarpentries, Radj Gervais, et al.BMC Cancer|April 5, 2018
Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional studyCorinne Vannimenus, Hélène Bricout, Olivier Le Rouzic, et al.Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.Journal of Neuroendocrinology|August 21, 2023
Surgery of primary lung carcinoid tumors at metastatic stage: A national study from the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN networkLucie Duponchelle, Eric Baudin, Fabien Subtil, et al.Pageof 6